Estimated market cap $307.59MShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Aug 6, 2026, last close Nov 13, 2026.100.85M shares, shares as of Aug 6, 2026CIK 1133416The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
5 buys · 44 sells
$4.68M sold, open market
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Galectin Therapeutics Inc.'s latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Galectin Therapeutics Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
74
13.9% of shares · 25 added
Latest 10-Q
Q2 2026
What changed in Galectin Therapeutics Inc.'s latest quarterly report, compared with the one before.
Filed Aug 14, 2026 · Quarter ended Jun 30, 2026
AI No AI summary for this 10-Q: management's discussion could not be compared, and the other sections did not change.
Compared with the 10-Q for the quarter ended Mar 31, 2026. Sections compared: risk factors and legal proceedings.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No open-market insider trades reported since Jul 14, 2026. Insiders have two business days to file.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
74 funds report GALT. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 16% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 15.78M reported shares by 100.85M shares, from the company’s SEC filing as of Aug 6, 2026.
98 funds hold the stock.
Q3 2026: 14% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202516%
Q3 202516%
Q4 202518%
Q1 202621%
Q2 202616%
Q3 2026 (so far)14%
Q3 2026. 10 new, 25 added to, 18 trimmed, 33 exited since Q2 2026.
Download CSVEvery fund that holds GALT, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
No recent congressional trades for this company.
Lobbying
What Galectin Therapeutics Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q2 2013
16
—
738,226
$3.1M
Q3 2013
26
+10
1.05M
$10.4M
Q4 2013
33
+7
1.56M
$12.6M
Q1 2014
55
+22
3.54M
$53.9M
Q2 2014
65
+10
4.32M
$59.7M
Q3 2014
63
-2
4.41M
$22.2M
Q4 2014
62
-1
3.76M
$13.0M
Q1 2015
62
0
4.07M
$13.6M
Q2 2015
58
-4
3.33M
$9.1M
Q3 2015
51
-7
2.66M
$7.0M
Q4 2015
57
+6
3.59M
$5.9M
Q1 2016
49
-8
3.07M
$4.4M
Q2 2016
50
+1
3.50M
$5.1M
Q3 2016
46
-4
3.04M
$3.4M
Q4 2016
43
-3
2.86M
$2.8M
Q1 2017
45
+2
3.72M
$8.5M
Q2 2017
52
+7
3.98M
$9.8M
Q3 2017
49
-3
3.89M
$8.3M
Q4 2017
49
0
3.74M
$12.5M
Q1 2018
62
+13
4.98M
$23.6M
Q2 2018
69
+7
5.60M
$35.6M
Q3 2018
61
-8
5.97M
$35.9M
Q4 2018
61
0
6.02M
$20.8M
Q1 2019
64
+3
7.30M
$37.3M
Q2 2019
76
+12
9.26M
$38.4M
Q3 2019
79
+3
9.35M
$34.3M
Q4 2019
78
-1
10.61M
$30.3M
Q1 2020
77
-1
9.68M
$19.0M
Q2 2020
75
-2
10.16M
$31.1M
Q3 2020
71
-4
10.07M
$26.9M
Q4 2020
78
+7
10.89M
$24.3M
Q1 2021
75
-3
9.94M
$22.7M
Q2 2021
75
0
7.92M
$25.3M
Q3 2021
70
-5
7.29M
$28.2M
Q4 2021
55
-15
7.50M
$15.5M
Q1 2022
60
+5
7.47M
$12.0M
Q2 2022
60
0
7.06M
$9.3M
Q3 2022
59
-1
6.94M
$11.3M
Q4 2022
61
+2
7.11M
$8.1M
Q1 2023
60
-1
7.17M
$15.1M
Q2 2023
60
0
7.28M
$10.5M
Q3 2023
60
0
9.07M
$17.4M
Q4 2023
66
+6
7.41M
$12.3M
Q1 2024
59
-7
7.99M
$19.1M
Q2 2024
73
+14
9.53M
$21.7M
Q3 2024
79
+6
9.78M
$26.9M
Q4 2024
94
+15
10.11M
$13.0M
Q1 2025
93
-1
10.39M
$12.7M
Q2 2025
86
-7
10.54M
$22.2M
Q3 2025
84
-2
10.38M
$44.0M
Q4 2025
98
+14
11.63M
$48.1M
Q1 2026
99
+1
13.94M
$38.8M
Q2 2026
98
-1
15.78M
$72.9M
Q3 2026
74
-24
13.99M
$54.2M
Each point is a quarter-end, from Q2 2013 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (363225202). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2013) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.